Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUFENTA PRESERVATIVE FREE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sufentanil is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors in the central nervous system, leading to activation of descending pain pathways and inhibition of nociceptive transmission.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Epidural administration for the management of pain during labor and delivery,Intravenous use as an analgesic supplement in general anesthesia,Intravenous use for the induction and maintenance of anesthesia,Off-label: Patient-controlled analgesia (PCA) for acute pain management
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
1-2 mcg/kg IV initially, then 0.15-0.3 mcg/kg/min IV infusion; doses up to 8 mcg/kg for anesthesia induction.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is approximately 2.5-3.5 hours in adults, 3-4 hours in neonates; clinical context: context-sensitive half-life increases with infusion duration (e.g., ~30 minutes after 2-hour infusion, ~45 min after 8-hour infusion).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized by CYP3A4 and CYP2C9 enzymes in the liver to N-desmethylsufentanil and other minor metabolites. Undergoes phase II conjugation before renal excretion.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (metabolites, <1% unchanged) and biliary; sufentanil is extensively metabolized in liver via N-dealkylation and O-demethylation, with metabolites primarily excreted in urine (approximately 80%) and feces (approximately 20%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 92-93% bound to plasma proteins, primarily α1-acid glycoprotein and albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vdss (steady-state volume of distribution) is approximately 1.5-2.5 L/kg in adults; higher in neonates (2-3 L/kg); indicates extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Intravenous: 100%; epidural: ~90-95% (due to vascular absorption); intrathecal: ~100% (but with minimal systemic absorption due to high lipid solubility); nasal: ~70-80%; transmucosal: ~50-60% (buccal).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No specific dose adjustment required; active metabolite normeperidine accumulates in renal failure, use with caution and monitor for CNS toxicity.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce to 25% of usual dose; monitor for prolonged effects.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Neonates and infants: 0.3-0.5 mcg/kg IV bolus; children: 0.2-0.5 mcg/kg IV bolus, then 0.1-0.3 mcg/kg/min IV infusion; dose based on ideal body weight.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Reduce initial dose by 50% and titrate slowly; increased sensitivity to respiratory depression and hypotension; monitor renal function as clearance may be reduced.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of respiratory depression, especially in non-opioid-tolerant patients and when used for acute pain management. Accidental ingestion or exposure can cause fatal respiratory depression in children. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression: Monitor oxygenation and ventilation closely; have resuscitation equipment available.,CNS depression: Additive effects with alcohol, sedatives, and other CNS depressants.,Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy may cause withdrawal in neonates.,Serotonin syndrome: Risk when used with serotonergic drugs.,Hypotension and bradycardia: May occur, especially during induction of anesthesia.,Biliary spasm: May cause spasm of the sphincter of Oddi.,Tolerance and dependence: Prolonged use can lead to physical and psychological dependence.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to sufentanil or any component of the formulation,Significant respiratory depression (in unmonitored settings or absence of resuscitative equipment),Acute or severe bronchial asthma,Known or suspected paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No known food interactions. Avoid alcohol due to additive CNS depression.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Sufentanil is Pregnancy Category C. There is no evidence of teratogenicity in animal studies at doses up to 2.5 times the human dose. However, sufentanil crosses the placenta and can cause neonatal respiratory depression and withdrawal if used chronically or at high doses near term. Use during labor and delivery may cause respiratory depression in the neonate. There are no adequate and well-controlled studies in pregnant women; use only if potential benefit justifies the potential risk to the fetus.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Sufentanil is excreted in human milk. The milk-to-plasma ratio is approximately 2:1. Breastfeeding infants may be exposed to low levels, but the clinical significance is unknown. The American Academy of Pediatrics considers opioids compatible with breastfeeding, but caution is advised due to potential for CNS depression in the infant. Monitor for drowsiness and feeding difficulties.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Pregnancy may alter pharmacokinetics of sufentanil due to increased volume of distribution, decreased plasma protein binding, and increased clearance. Dose requirements may be increased to achieve desired analgesic effect. However, careful titration is needed to avoid maternal or fetal toxicity. Epidural dosing may require adjustments; general dosing guidelines for obstetrics should be followed. No specific dose adjustment in pregnancy is universally recommended; individualize based on response and adverse effects.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Sufentanil is a highly potent mu-opioid agonist (5-10x fentanyl). Use preservative-free formulation for neuraxial administration. Monitor for delayed respiratory depression, especially with epidural use. Naloxone reversal may require higher doses due to high receptor affinity. Co-administration with benzodiazepines or other CNS depressants increases risk of severe respiratory depression. Have resuscitation equipment immediately available.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
This medication causes drowsiness and dizziness; do not drive or operate heavy machinery.,Avoid alcohol and other sedatives unless prescribed by your doctor.,Serious breathing problems can occur, especially in the first 24 hours after administration.,Inform your doctor if you have sleep apnea, lung disease, or are taking other medications.,Neuraxial administration may cause itching, nausea, or urinary retention—report these symptoms.,Do not stop taking or change dose without medical supervision due to risk of withdrawal.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUFENTA PRESERVATIVE FREE vs ACTIQ, answered by our medical review team.
SUFENTA PRESERVATIVE FREE is a Opioid Analgesic that works by Sufentanil is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors in the central nervous system, leading to activation of descending pain pathways and inhibition of nociceptive transmission.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUFENTA PRESERVATIVE FREE and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUFENTA PRESERVATIVE FREE is: 1-2 mcg/kg IV initially, then 0.15-0.3 mcg/kg/min IV infusion; doses up to 8 mcg/kg for anesthesia induction.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUFENTA PRESERVATIVE FREE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUFENTA PRESERVATIVE FREE is classified as Category C. Sufentanil is Pregnancy Category C. There is no evidence of teratogenicity in animal studies at doses up to 2.5 times the human dose. However, sufentanil crosses the placenta and c. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.